Headache News

SAN DIEGO — Patients with migraine who received daytime psilocybin experienced reduced REM sleep, with effects lasting beyond the day of administration, according to a poster at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — The stigma that accompanies migraine is universal and often affects more than one personal or professional relationship, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO – Spontaneous intracranial hypotension led to significant physical, mental and quality of life impact for a cohort of those with the condition, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO —Individuals with episodic migraine had lower nutrient intake on days with nausea or vomiting compared with days without nausea, according to a poster from the American Headache Society Annual Scientific Meeting.

SAN DIEGO — A vaporized combination of THC and CBD was the most efficacious of four cannabis choices for acute moderate to severe migraine at 2 hours, according to an expert at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — AI-based models are currently best utilized as a predictor of headache, but show promise for expansion into the health care continuum, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.

DENVER – Most with menstrual migraine utilize only acute treatments, rather than preventive measures, to address their symptoms, according to research presented at the American Academy of Neurology annual meeting.

DENVER — Treatment with 10 mg zavegepant nasal spray was associated with a higher likelihood of pain freedom compared with placebo at 2 hours post dose, according to a presentation at the American Academy of Neurology annual meeting.